01 Aug 2018

GE HEALTHCARE, LANTHEUS BEGIN A PHASE 3 CLINICAL TRIAL OF FLURPIRIDAZ TO TREAT CAD

GE Healthcare and Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease (CAD), the most common form of heart disease.1 CAD affects an estimated

0